Cingulate (CING) Other Accumulated Expenses (2021 - 2026)
Cingulate's (CING) quarterly Other Accumulated Expenses came in at $87742.0 in Q4 2025, up 154.55% YoY from $34469.0 in Q4 2024, and up 47.58% on a QoQ basis from $59455.0 in Q3 2025.
Cingulate (CING) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Other Accumulated Expenses data on file, last reported at $87742.0 in Q4 2025.
- Quarterly Other Accumulated Expenses rose 154.55% year-over-year to $87742.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87742.0 (up 154.55% YoY) and the FY2025 annual result came in at $87742.0, up 154.55% from the prior year.
- Other Accumulated Expenses climbed to $87742.0 in Q4 2025, from $59455.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $326742.0 in Q3 2022 to a low of $16107.0 in Q2 2023.
- A 5-year average of $106049.4 and a median of $55363.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses sank 94.87% — and 2024, when it soared 159.66%.
- Tracing CING's Other Accumulated Expenses over 5 years: stood at $295595.0 in 2021, then slumped by 81.27% to $55363.0 in 2022, then grew by 20.83% to $66897.0 in 2023, then slumped by 48.47% to $34469.0 in 2024, then soared by 154.55% to $87742.0 in 2025.
- The last three Other Accumulated Expenses figures came in at $87742.0 (Q4 2025), $59455.0 (Q3 2025), and $35586.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27,275.00 |
| Dec 31, 2025 | 87,742.00 |
| Sep 30, 2025 | 59,455.00 |
| Jun 30, 2025 | 35,586.00 |
| Mar 31, 2025 | 22,809.00 |
| Dec 31, 2024 | 34,469.00 |
| Sep 30, 2024 | 27,450.00 |
| Jun 30, 2024 | 25,850.00 |
| Mar 31, 2024 | 74,569.00 |
| Dec 31, 2023 | 66,897.00 |
| Sep 30, 2023 | 28,127.00 |
| Jun 30, 2023 | 16,107.00 |
| Mar 31, 2023 | 28,718.00 |
| Dec 31, 2022 | 55,363.00 |
| Sep 30, 2022 | 326,742.00 |
| Jun 30, 2022 | 314,097.00 |
| Mar 31, 2022 | 303,263.00 |
| Dec 31, 2021 | 295,595.00 |